A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance

The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify novel molecular targets that are capable to increase GISTs sensitivity to the current therapeutic regimens. Secondary resistance to IM in G...

Full description

Bibliographic Details
Main Authors: Sergei Boichuk, Aigul Galembikova, Pavel Dunaev, Elena Valeeva, Elena Shagimardanova, Oleg Gusev, Svetlana Khaiboullina
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:Molecules
Subjects:
gastrointestinal stromal tumor cells (GISTs)
imatinib (IM)
FGFR2α
resistance
receptor tyrosine kinase (RTK) inhibitors
chemotherapeutic drugs
Online Access:https://www.mdpi.com/1420-3049/22/12/2152

Internet

https://www.mdpi.com/1420-3049/22/12/2152

Similar Items